Welcome to LookChem.com Sign In|Join Free

CAS

  • or

2255-14-3

Post Buying Request

2255-14-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

2255-14-3 Usage

Description

alpha-D-Galactose 1-phosphate (and/or unspecified salts) is a monosaccharide derivative with a phosphate group attached to the anomeric center in an alpha-configuration. It is a key intermediate in the metabolism of various sugars and plays a significant role in cellular processes.

Uses

Used in Pharmaceutical Industry:
alpha-D-Galactose 1-phosphate (and/or unspecified salts) is used as an intermediate in the synthesis of various pharmaceutical compounds, particularly those targeting the metabolism of sugars. Its role in cellular processes makes it a potential candidate for the development of drugs aimed at modulating sugar metabolism-related diseases.
Used in Research and Development:
In the field of research and development, alpha-D-Galactose 1-phosphate (and/or unspecified salts) serves as an essential compound for studying the biochemical pathways and mechanisms involved in sugar metabolism. It can be used to investigate the role of this intermediate in various metabolic processes and its potential as a therapeutic target for diseases related to sugar metabolism dysregulation.
Used in Diagnostic Applications:
alpha-D-Galactose 1-phosphate (and/or unspecified salts) can be employed in the development of diagnostic tools and tests to detect and monitor sugar metabolism-related disorders. Its presence or levels in biological samples can provide valuable information about the status of an individual's metabolic health and the effectiveness of treatments targeting sugar metabolism.
Used in Biochemical Education:
As a key intermediate in sugar metabolism, alpha-D-Galactose 1-phosphate (and/or unspecified salts) is an important compound for teaching and learning purposes in the field of biochemistry and molecular biology. It can be used to illustrate the complexities of metabolic pathways and the role of specific intermediates in cellular processes.

Check Digit Verification of cas no

The CAS Registry Mumber 2255-14-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,2,5 and 5 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 2255-14:
(6*2)+(5*2)+(4*5)+(3*5)+(2*1)+(1*4)=63
63 % 10 = 3
So 2255-14-3 is a valid CAS Registry Number.
InChI:InChI=1/C6H13O9P/c7-1-2-3(8)4(9)5(10)6(14-2)15-16(11,12)13/h2-10H,1H2,(H2,11,12,13)/t2-,3+,4+,5-,6?/m1/s1

2255-14-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name D-galactopyranose 1-phosphate

1.2 Other means of identification

Product number -
Other names galactose-1-phosphate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:2255-14-3 SDS

2255-14-3Relevant articles and documents

Toward Automated Enzymatic Glycan Synthesis in a Compartmented Flow Microreactor System

Heinzler, Raphael,Fisch?der, Thomas,Elling, Lothar,Franzreb, Matthias

supporting information, p. 4506 - 4516 (2019/08/20)

Immobilized microfluidic enzyme reactors (IMER) are of particular interest for automation of enzyme cascade reactions. Within an IMER, substrates are converted by paralleled immobilized enzyme modules and intermediate products are transported for further conversion by subsequent enzyme modules. By optimizing substrate conversion in the spatially separated enzyme modules purification of intermediate products is not necessary, thus shortening process time and increasing space-time yields. The IMER enables the development of efficient enzyme cascades by combining compatible enzymatic reactions in different arrangements under optimal conditions and the possibility of a cost-benefit analysis prior to scale-up. These features are of special interest for automation of enzymatic glycan synthesis. We here demonstrate a compartmented flow microreactor system using six magnetic enzyme beads (MEBs) for the synthesis of the non-sulfated human natural killer cell-1 (HNK-1) glycan epitope. MEBs are assembled to build compartmented enzyme modules, consisting of enzyme cascades for the synthesis of uridine 5′- diphospho-α- d-galactose (UDP-Gal) and uridine 5′-diphospho-α-d-glucuronic acid (UDP-GlcA), the donor substrates for the Leloir glycosyltransferases β4-galactosyltransferase and β3-glucuronosyltransferase, respectively. Glycan synthesis was realized in an automated microreactor system by a cascade of individual enzyme module compartments each performing under optimal conditions. The products were analyzed inline by an MS-system connected to the microreactor. The high synthesis yield of 96% for the non-sulfated HNK-1 glycan epitope indicates the excellent performance of the automated enzyme module cascade. Furthermore, combinations of other MEBs for nucleotide sugars synthesis with MEBs of glycosyltransferases have the potential for a fully automated and programmed glycan synthesis in a compartmented flow microreactor system. (Figure presented.).

β-Glucose-1,6-Bisphosphate stabilizes pathological phophomannomutase2 mutants in vitro and represents a lead compound to develop pharmacological chaperones for the most common disorder of glycosylation, PMM2-CDG

Monticelli, Maria,Liguori, Ludovica,Allocca, Mariateresa,Andreotti, Giuseppina,Cubellis, Maria Vittoria

, (2019/10/22)

A large number of mutations causing PMM2-CDG, which is the most frequent disorder of glycosylation, destabilize phosphomannomutase2. We looked for a pharmacological chaperone to cure PMM2-CDG, starting from the structure of a natural ligand of phosphomannomutase2, α-glucose-1,6-bisphosphate. The compound, β-glucose-1,6-bisphosphate, was synthesized and characterized via 31P-NMR. β-glucose-1,6-bisphosphate binds its target enzyme in silico. The binding induces a large conformational change that was predicted by the program PELE and validated in vitro by limited proteolysis. The ability of the compound to stabilize wild type phosphomannomutase2, as well as frequently encountered pathogenic mutants, was measured using thermal shift assay. β-glucose-1,6-bisphosphate is relatively resistant to the enzyme that specifically hydrolyses natural esose-bisphosphates.

Facile enzymatic synthesis of sugar 1-phosphates as substrates for phosphorylases using anomeric kinases

Liu, Yuan,Nishimoto, Mamoru,Kitaoka, Motomitsu

, p. 1 - 4 (2015/02/19)

Three sugar 1-phosphates that are donor substrates for phosphorylases were produced at the gram scale from phosphoenolpyruvic acid and the corresponding sugars by the combined action of pyruvate kinase and the corresponding anomeric kinases in good yields. These sugar 1-phosphates were purified through two electrodialysis steps. α-d-Galactose 1-phosphate was finally isolated as crystals of dipotassium salts. α-d-Mannose 1-phosphate and 2-acetamido-2-deoxy-α-d-glucose 1-phosphate were isolated as crystals of bis(cyclohexylammonium) salts.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 2255-14-3